Integral Molecular announced the expansion of its two proprietary antibody characterization platforms, Shotgun Mutagenesis Epitope Mapping and the Membrane Proteome Array.
PHILADELPHIA, April 16, 2019 /PRNewswire/ -- Integral Molecular, the industry leader in membrane protein solutions, today announced the expansion of its two proprietary antibody characterization platforms, Shotgun Mutagenesis Epitope Mapping and the Membrane Proteome Array (MPA). Integral Molecular recently acquired office and laboratory space, which enabled the company to double its antibody characterization capabilities.
“Businesses like Integral Molecular are creating jobs and contributing to the vibrancy of Philadelphia’s biosector. We’re thrilled that Integral Molecular has chosen to start, grow, and expand right here at uCity Square,” says Steve Zarrilli, President & CEO of University City Science Center. “Integral Molecular’s trajectory exemplifies the services and support offered by the Science Center and facilities available at uCity Square.”
The expansion is being driven by recent MPA Target Discovery partnerships and a surge of Shotgun Mutagenesis Epitope Mapping projects, prompting the need for additional space and personnel.
“Integral Molecular is in an exciting growth phase where we’re expanding our teams, launching new products, and reaching new markets,” says Ben Doranz, President and CEO of Integral Molecular. “To achieve these goals, we’re dedicating additional resources to antibody characterization, a key component of our suite of membrane protein solutions.”
About Integral Molecular
Integral Molecular (www.integralmolecular.com) is the industry leader in membrane protein solutions, with a pipeline of therapeutic antibodies against GPCRs, ion channels, transporters, and immuno-oncology targets. Built on the company’s extensive experience optimizing membrane proteins, Integral Molecular’s technology suite enables the isolation, characterization, and engineering of MAbs against otherwise intractable targets. The company currently has therapeutic programs focused on cancer, pain, immunity, and metabolic diseases.
Contact:
Integral Molecular, Inc.
Ben Doranz, PhD, President and CEO
215-966-6061
info@integralmolecular.com
www.integralmolecular.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/integral-molecular-doubles-antibody-characterization-capacity-within-philadelphias-science-center-300832409.html
SOURCE Integral Molecular
